Transgene receives FDA IND Clearance for Lead myvac(TM) Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

information fournie par Boursorama •13/05/2019 à 07:30

Phase 1 clinical trial, expected to start in H2 2019, will be co-funded by Transgene and its collaboration partner NEC



Strasbourg, France, May 13, 2019, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1 clinical trial of its lead myvac(TM) candidate TG4050 as a potential treatment for ovarian cancer patients after first-line surgery and chemotherapy.

TG4050 is an individualized MVA-based immunotherapy derived from the myvac(TM) platform. It has been designed to stimulate and educate the immune system of patients to recognize and destroy tumor cells. Tumor cells accumulate mutations and each patient has a set of mutations that are unique to his tumor. TG4050 is designed to target a panel of patient specific mutations selected using a NEC's Neoantigen Prediction System
.../...